search
for
 About Bioline  All Journals  Testimonials  Membership  News


Biotecnologia Aplicada
Elfos Scientiae
ISSN: 0684-4551
Vol. 14, No. 1, 1997, pp. 31-32
Bioline Code: ba97003
Full paper language: Spanish
Document type: Research Article
Document available free of charge

Biotecnologia Aplicada, Vol. 14, No. 1, 1997, pp. 31-32

 en
Bernal, Francisco Hernandez; Lopez, Tania Gonzalez; Rol, Giselle Penton & Lopez-Saura, Pedro

Abstract

A double-blind, phase-I clinical trial was carried out in healthy volunteers to know the penetrability of topically applied epidermal growth factor (EGF). Twenty-four individuals were randomly distributed in three groups. The treated groups received EGF (10 or 100 ug/g) in 1 % silver sulfadiazine cream. The control group received the latter cream alone. The serum EGF concentration was measured by an ELISA. Negligible penetrability was obtained despite a 10-fold higher concentration, compared to the therapeutic dose, was used. This low penetrability contributes to the safety of the product reducing the possibility of systemic or distant adverse effects.

Keywords
clinical trial, epidermal growth factor, EGF, phase I

 
 es Estudio de penetrabilidad del factor de crecimiento epidermico aplicado topicamente en voluntarios sanos
Bernal, Francisco Hernandez; Lopez, Tania Gonzalez; Rol, Giselle Penton & Lopez-Saura, Pedro

Resumen

Se realizoun ensayo clinico Fase I, controlado y a doble ciegas en voluntarios sanos, para conocer la penetrabilidad del factor de crecimiento epidermico (EGF) aplicado topicamente. Veinticuatro sujetos fueron distribuidos aleatoriamente en tres grupos: dos de estudio y el otro de control. En los primeros se empleo el factor de crecimiento epidermico humano recombinante (10 o 100 ug/g) en crema hidrofila de sulfadiacina de plata al 1 %, y en el control, crema de sulfadiacina de plata al 1 %. Se midio la concentracion de EGF en el suero mediante un ELISA y se obtuvieron umbrales despreciables de penetrabilidad del peptido, aun cuando se emplearon concentraciones del principio activo diez veces superiores a las utilizadas en la formulacion administrada a pacientes. La baja penetrabilidad contribuye a la seguridad del producto, con lo cual se reduce la posibilidad de efectos adversos sistemicos o a distancia.

Palabras-clave
ensayo clinico, factor de crecimiento epidermico, EGF, Fase I

 
© Copyright 1997 Elfos Scientiae
Alternative site location: http://elfosscientiae.cigb.edu.cu/Archivo.asp?Id=6

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2024, Site last up-dated on 01-Sep-2022.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Google Cloud Platform, GCP, Brazil